Home › Myeloproliferative Neoplasms
Myeloproliferative Neoplasms clinical trials recruiting in the U.S.
51 studies for Myeloproliferative Neoplasms are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX17 studies
- New York City, NY15 studies
- Boston, MA15 studies
- Miami, FL11 studies
- Salt Lake City, UT10 studies
- Durham, NC10 studies
- Seattle, WA10 studies
- Baldwin Park, CA10 studies
- St. Louis, MO10 studies
- Milwaukee, WI10 studies
- Columbus, OH9 studies
- Winston-Salem, NC9 studies
- Portland, OR9 studies
- Tampa, FL9 studies
- Chicago, IL9 studies
- Birmingham, AL9 studies
- Atlanta, GA9 studies
- Cleveland, OH9 studies
- Baltimore, MD8 studies
- Philadelphia, PA8 studies
- Nashville, TN7 studies
- Mountain View, CA7 studies
- Irvine, CA7 studies
- Charlotte, NC7 studies
- Kansas City, MO7 studies
- Ann Arbor, MI7 studies
- Los Angeles, CA7 studies
- Sacramento, CA6 studies
- Phoenix, AZ6 studies
- Jacksonville, FL6 studies
- Queens, NY5 studies
- Rochester, MN5 studies
- Minneapolis, MN5 studies
- Cedar Rapids, IA5 studies
- San Francisco, CA5 studies
- Pittsburgh, PA5 studies
- Charlottesville, VA5 studies
- Omaha, NE5 studies
- Edison, NJ5 studies
- Oklahoma City, OK4 studies
By state
- Alabama9 studies
- Arizona9 studies
- Arkansas4 studies
- California18 studies
- Colorado6 studies
- Connecticut5 studies
- Florida14 studies
- Georgia11 studies
- Hawaii3 studies
- Idaho4 studies
- Illinois10 studies
- Indiana4 studies
- Iowa5 studies
- Kansas7 studies
- Kentucky3 studies
- Louisiana4 studies
- Maine4 studies
- Maryland9 studies
- Massachusetts16 studies
- Michigan9 studies
- Minnesota8 studies
- Mississippi4 studies
- Missouri10 studies
- Montana3 studies
- Nebraska5 studies
- New Jersey5 studies
- New Mexico4 studies
- New York15 studies
- North Carolina14 studies
- North Dakota3 studies
- Ohio14 studies
- Oklahoma5 studies
- Oregon10 studies
- Pennsylvania10 studies
- Rhode Island4 studies
- South Carolina5 studies
- Tennessee9 studies
- Texas19 studies
- Utah10 studies
- Vermont3 studies
- Virginia7 studies
- Washington10 studies
- Wisconsin10 studies
Recently updated studies
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07441694Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
RecruitingPhase 1/2
Ages 12 to 120 · All sexes · Updated Nov 13, 2026 · NCT06303193Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Nov 10, 2026 · NCT03589729Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Nov 9, 2026 · NCT05554406Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06523556Asciminib Roll-over Study
RecruitingPhase 4
Ages 7 to 100 · All sexes · Updated Nov 9, 2026 · NCT04877522MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05564390Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 29, 2026 · NCT06265584A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07469891Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06661915A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07849231Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Oct 26, 2026 · NCT06013423CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06059391A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT07020533Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05320198Therapeutic RSK1 Targeting in Myeloid Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07379125Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05423691Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
Ages 1 to 60 · All sexes · Updated Oct 20, 2026 · NCT03970096Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Recruiting
Up to age 30 · All sexes · Updated Oct 20, 2026 · NCT06421155Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Recruiting
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT05745285Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Oct 9, 2026 · NCT06315309Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 18, 2026 · NCT03630991Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.